 Poster presentations introduce data demonstrating KER-050 robustly promoted hematopoiesis in multiple animal species in preclinical studies and support a potentially novel mechanism of action. Oral presentation on a novel ALK2 kinase inhibitor that suppressed hepcidin production and subsequently ameliorated anemia in a mouse model of iron-refractory iron deficiency anemia. LEXINGTON, Mass., June 12, 2020 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced updated data from its Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effects of ascending dose levels of KER-050 in healthy post-menopausal women, along with preclinical data on KER-050 from multiple animal models and additional preclinical data evaluating the role of ALK2 inhibition in regulating hepcidin and serum iron. 